Genes associated with depression and coronary artery disease are enriched for

inflammation and cardiomyopathy-associated pathways.

Kritika Singh[1,2], Hyunjoon Lee[3,4,5]*, Julia M Sealock[1,2]*, Tyne Miller-Flemming[1,2], Peter

Straub[1,2], Nancy J. Cox[1,2], Quinn S. Wells[6], Jordan W. Smoller[3,4,5], Emily C. Hodges[2,7], Lea

K. Davis[1,2,8,9,10]

*These authors contributed equally

#Corresponding author

[1]Division of Genetic Medicine, Department of Medicine
Vanderbilt University Medical Center
Nashville, TN, 37232, USA
11
12   [2]Vanderbilt Genetics Institute
13   Vanderbilt University Medical Center
14   Nashville, TN, 37232, USA
15
16   [3]Psychiatric and Neurodevelopmental Genetics Unit
17   Center for Genomic Medicine
18   Massachusetts General Hospital
19   Boston, MA, 02114, USA
20
21   [4]Center for Precision Psychiatry
22   Department of Psychiatry
23   Massachusetts General Hospital
24   Boston, MA, 02114, USA
25
26   [5]Stanley Center for Psychiatric Research
27   Broad Institute of Harvard and MIT
28   Cambridge, MA, 02114,USA
29
30   [6]Division of Cardiovascular Medicine, Department of Medicine,
31   Vanderbilt University Medical Center,
32   Nashville, TN, 37232, USA
33
[7]Department of Biochemistry,
Vanderbilt University School of Medicine,

Nashville, TN, 37232, USA

[8]Department of Molecular Physiology and Biophysics

Vanderbilt University Medical Center

Nashville, TN, 37232, USA

[9]Department of Psychiatry and Behavioral Sciences

Vanderbilt University Medical Center

Nashville, TN, 37232, USA

[10]Departments of Medicine and Biomedical Informatics

Vanderbilt University Medical Center

Nashville, TN, 37232, USA

Total word count of manuscript: 4,656 Words

Short Title: Genes shared between depression and CAD

Abstract (140 words)

Background: Depression and Coronary Artery Disease (CAD) are highly comorbid conditions.

Approximately 40% of individuals who have one diagnosis will also develop the other within

their lifetime. Prior research indicates that polygenic risk for depression increases the odds of

developing CAD even in the absence of clinical depression. However, the specific genes and

pathways involved in comorbid depression-CAD remain unknown.

Results: We identified genes that are significantly associated with both depression and CAD,

and are enriched for pathways involved in inflammation and for previous association with

cardiomyopathy. We observed increased rate of prevalent, but not incident, cardiomyopathy

cases in individuals with comorbid depression-CAD compared to those with CAD alone in three

electronic large health record (EHR) datasets.

Conclusions: The results of our study implicate genetically regulated inflammatory mechanisms

in depression-CAD. Our results also raise the hypothesis that depression-associated CAD may be

enriched for cardiomyopathy.

Clinical Perspective

A. What's New?

1. Gene associations shared between depression and CAD are enriched for prior

72   association with cardiomyopathy phenotypes.

73   *2.* Cardiomyopathy is significantly more prevalent in individuals with comorbid

74   depression-CAD than in CAD or depression alone.

75   *B. What are the Clinical Implications?*

76   1. Our work suggests that individuals with comorbid depression-CAD may benefit from

77   screening for cardiomyopathy.

79 Non-Standard Abbreviations and Acronyms

Abbreviation	Definition
CAD	Coronary artery disease
CI	Confidence interval
CAD	Coronary Artery Disease
CVD	Cardiovascular disease
EHR	Electronic health record
GWAS	Genome-wide association study
ICD	International Classification of Diseases
LD	Linkage disequilibrium
MD	Major depression
MDD	Major depressive disorder
MHC	Major histocompatibility complex
MR	Mendelian randomisation
OR	Odds ratio
PGS	Polygenic score
SNP	Single nucleotide polymorphism
VUMC	Vanderbilt University Medical Center

Introduction

Chronic complex diseases such as cardiovascular disease (CVD) are the primary drivers of premature death among individuals with psychiatric disorders. Approximately 17 to 44 percent of patients with coronary artery disease (CAD), the most common type of CVD, also have a diagnosis of major depression (MDD), a common mental health diagnosis[1]. Several studies suggest that these two conditions are biologically related. A diagnosis of major depression is associated with increased 18-month cardiac mortality among CAD patients; and CAD with comorbid MDD reduces lifespan by 15-20 years[2–5]. However, despite the frequency and high mortality rate of comorbid CAD with depression and/or MDD, hereafter referred to as (major) depressive CAD or (m)dCAD, the biological relationship between these conditions remains poorly understood.

Previously, we demonstrated that common genetic risk for depression identified by genome-wide association studies (GWAS) and quantified in the form of polygenic risk scores (PRS), is associated with a diagnosis of CAD and myocardial infarction in a healthcare-based clinical population[6]. High genetic liability to MDD was associated with increased risk of cardiovascular disease even among patients with no history of psychiatric illness and after accounting for cardiovascular disease risk factors[6]. Shared inflammatory processes provide one possible explanation for these findings[7,8]. Studies show that as CAD progresses, changes in the levels of inflammatory biomarkers such as C-Reactive protein (CRP), leukocytes, monocytes and inflammation associated prothrombotic markers including platelets, can be observed[9–11]. Similarly, onset and severity of depression is associated with changes in the levels of immune and inflammatory factors including leukocytes, CRP, and platelets[12–22]. Neuroinflammation and

peripheral inflammation are hypothesized to play an important role in both MDD and CAD

respectively, providing a potential common biological pathway that may link

neuroinflammation in depression together with atherosclerotic inflammation in CAD[7,8].

Consortium efforts over the past decade have yielded results from large genome-wide

association studies of depression, and independently, CAD[23,24]. These studies provide a map of

statistical associations between common single nucleotide polymorphisms (SNPs) and each

diagnosis, respectively. However, the genes that are implicated by these SNP associations must

also be identified to define the biological pathways that might be shared between these

conditions. Transcriptome wide association scans (TWAS) employ functional data to map SNPs

to genes based on their ability to regulate gene expression[25]. In this study, we first used the

TWAS method S-MultiXcan to map depression and CAD SNP-associations to the genes they

regulate using cross-tissue expression quantitative trait loci (eQTL) annotations[25]. We then

performed a series of enrichment and pathway analyses to characterize the gene set that was

significantly associated with both depression and CAD. Our findings suggest that genes

associated with both CAD and depression are enriched for both inflammatory pathways and

genes previously associated with cardiomyopathy.

Next, we developed a clinical hypothesis based on these findings and tested it in three

separate large electronic health records (EHR) data sets –Vanderbilt University Medical Center

EHR, All of Us Research Program, and Mass-General Brigham EHR. At each site, we find that the

rate of prevalent cardiomyopathy is significantly higher in subjects with (m)dCAD compared to

those with CAD alone. Taken together, results of our study link depression and CAD through

genetically controlled inflammatory mechanisms, and further suggest a relationship between

(m)dCAD and cardiomyopathy.

Materials and Methods

Genome-wide Association Study Data – Coronary Artery Disease

We utilized publicly available summary statistics from a recently published GWAS of

CAD as the foundation for our MetaXcan and S-MultiXcan analyses[23]. This study included a

genome-wide meta-analysis of CAD cases and controls from the UK Biobank (UKBB) and

CARDIoGRAMplusC4D[23]. CAD was defined in the UKBB by ICD10 codes (I21 – I25), procedural

codes (K40-K46, K49, K50 and K75), and self-report of heart attack/myocardial infarction,

coronary angioplasty +/- stent, coronary artery bypass graft surgery, or triple heart bypass.

Controls were defined by the absence of features used to define cases and the absence of any

family history of "heart disease". Application of these criteria resulted in 34,541 CAD cases and

261,984 controls. The second sample used in this meta-analysis was the CARDIoGRAMplusC4D

GWAS which itself was a meta-analysis of twenty-eight studies of European or South Asian

descent populations. CAD was operationally defined differently across the cohorts, but all

definitions relied on clinical or procedural markers of CAD, evidence of myocardial infarction, or

imaging data consistent with a CAD diagnosis (PMC3679547). The CARDIoGRAMplusC4D GWAS

included 63,746 CAD cases and 130,681 controls. The meta-analysis of UKBB and

CARDIoGRAMplusC4D totaled 122,733 CAD cases and 424,528 controls.

Genome-wide Association Study Data – Depression

We used summary statistics from the PGC and UKBB as the base for the MetaXcan

analysis of depression[24]. The genome-wide association meta-analysis for depression included

170,756 cases and 329,443 controls. These results included summary statistics from a meta-

analysis of the 33 cohorts of the Psychiatric Genomics Consortium as described in Wray et al.

(2018), (https://doi.org/10.1038/s41588-018-0090-3) and the broad depression phenotype in

the full release of the UKBB as described in (Howard et al. (2018),

https://doi.org/10.1038/s41467-018-03819-3). The broad depression phenotype in UKBB

included self-reported help-seeking behavior for "nerves, anxiety, tension or depression (once

at any visit)" from a general practice physician or a psychiatrist. Secondly, a subject was defined

as a case if there was a primary or secondary diagnosis of a depressive mood disorder from

linked hospital admission records (UK Biobank fields: 41202 and 41204; ICD codes: F32—Single

episode depression, F33—Recurrent depression, F34—Persistent mood disorders, F38—Other

mood disorders and F39—Unspecified mood disorders). The remaining respondents were

classed as controls if they answered "No" to both questions on all assessments. For the PGC

sample, cases were those who met international consensus criteria (DSM-IV, ICD-9, or ICD-10)

for a lifetime diagnosis of MDD established using structured diagnostic instruments from

assessments by trained interviewers, clinician-administered checklists, or medical record

review. Controls in most samples were screened for the absence of lifetime MDD (22/29

samples) or randomly selected from the population.

Statistical Analysis of Genetic Data

S-MultiXcan Analysis of Depression and CAD GWAS Summary Statistics

Predicted expression models of 22,207 genes across 49 tissues were developed

(supplementary materials) as previously described using data from the Genotype Tissue

Expression Project[25,26]. These models were then used to train gene-based predicted

associations for each set of summary statistics described above[25,26]. The subsequent

associations with CAD and depression were tested using a multivariate regression model

(Summary-MultiXcan or S-MultiXcan) which uses cross-tissue eQTL information[25]. S-MultiXcan

infers the gene-level MultiXcan association results, using univariate S-PrediXcan results and LD

information from a reference panel (i.e., the GTEx data set). Correlations between tissues are

accounted for using a pseudo-inverse approach which applies a singular value decomposition

(SVD) of the covariance matrix to keep only the components of large variation.

We used a Bonferroni correction to adjust the statistical significance threshold for

20,971 gene-based tests in the CAD MetaXcan analysis ($p < 2.38e-06$) and 20,945 gene-based

tests in the depression MetaXcan analysis ($p < 2.38e-06$).

Enrichment Analysis of Gene-based Association Results (Depression and CAD)

After identifying genes associated with either depression or CAD, we determined

whether genes associated with both CAD and depression (n=185) were more abundant than

expected by chance, based on the number of genes significantly associated with each

phenotype independently. We performed a hypergeometric test using the hyper R package and

the publicly available website http://nemates.org/MA/progs/overlap_stats.html.

Gene Set Enrichment Analyses (GSEA)

We used the Gene Set Enrichment Analysis Web-based Tool (http://www.gsea-

msigdb.org/gsea/msigdb/annotate.jsp) to functionally annotate the pathways for the 185 genes

associated with *both* depression and CAD. We restricted our analysis to the 'canonical

pathways' class with FDR q-values less than 0.05 and the GTEx compendium expression profiles.

There were 2,982 pathways, composed of 40,786 genes, tested in the null 'background' set,

provided by GSEA.

<u>Description of Clinical Populations</u>

Vanderbilt University Medical Center (VUMC) Electronic Health Record (EHR)

Vanderbilt University Medical Center (VUMC) is a tertiary care center that provides

inpatient and outpatient care in middle Tennessee and surrounding communities. The VUMC

electronic health record (EHR) system was established in 1990 and includes data on billing

codes from the International Classification of Diseases, 9th and 10th editions (ICD-9 and ICD-

10), Current Procedural Terminology (CPT) codes, laboratory values, reports, and clinical

documentation. A fully de-identified mirror image of the EHR, called the Synthetic Derivative, is

available to Vanderbilt faculty for research purposes[27].

Massachusetts General Brigham (MGB) EHR

Mass General Brigham (MGB) is a hospital network that includes Massachusetts General

Hospital, Brigham and Women's hospital, and other community and specialty hospitals in

Boston area. The data source of MGB EHR is MGB Research Patient Data Registry (RPDR;

https://rpdrssl.partners.org), an EHR database which spans more than 20 years of data from

over 6.5 million patients and includes data on diagnoses (billing codes; ICD-9 and ICD-10 codes),

procedures (CPT codes), laboratory values, and clinical notes. Data floors were applied to the

MGB RPDR to include only patients with at least one clinical note and three visits since 2005

with visit more than 30 days apart.

All of Us Research Program

We used data from the *All of Us* Research Program, a multi-ancestry population-based cohort

that contains various forms of information on individuals[28]. This data repository enrolls

participants 18 years of age or older and contains their demographic and medical record-based

information. The data for disease diagnosis was collected using billing codes and was the

converted to phecodes.

Phenotypic analysis in the Synthetic Derivative

Informed by results of the genomic analyses, we first investigated the prevalence of

cardiomyopathy in three mutually exclusive groups of patients in the VUMC-EHR including

those who had a diagnosis of (1) depression or major depression *without* comorbid CAD (dep),

(2) CAD *without* comorbid depression (CAD), and (3) CAD *with* comorbid depression or major

depression ((m)dCAD)(Table S1). To reduce missingness of clinical data and enrich the sample

for patients who receive their primary care at VUMC, we applied a simple "medical home"

heuristic requiring the presence of any five codes on different days over a period of at least

three years. We selected the cohort of individuals meeting these criteria who also had not been

included in the VUMC BioBank which resulted in a total of 988,002 individuals. The genotyped

sample was held out of this analysis to maintain its independence for future related research

studies including genomic data.

We defined dep-only, CAD-only, and (m)dCAD using phecodes which are higher order

combinations of at least two related ICD codes, occurring on two different days, using the R

PheWAS package. Specifically, "CAD-only" cases required the presence of phecode 411.4 and

absence of 296.2 phecode (N = 47,351), "dep-only" cases included phecode 296.2 and absence

of 411.4 phecode (N = 57,069) and (m)dCAD required the presence of a phecode for both CAD

and depression (N = 6,725). We next calculated the prevalence of cardiomyopathy, indicated by

the presence of one or more of the following phecodes "425.1", "425.11", "425.12", "425.8",

"425". We then compared the prevalence of cardiomyopathy diagnoses between each

diagnostic group using Pearson's Chi-squared test and Fisher's exact T-test.

We then used a logistic regression model to determine whether cardiomyopathy was

indeed more prevalent among patients with (m)dCAD, compared to CAD alone, after controlling

for potential confounding. Cases were defined as those with cardiomyopathy, controls were

those without cardiomyopathy. The exposure was defined as depression, and features known

to associate with both depression and cardiomyopathy, age, race, sex, record median BMI, type

2 diabetes (T2D; Phecode = 250.2), tobacco use disorder (TUD; Phecode = 318) and

hypertension (Phecodes = 401, 415.21, 453), were included as covariates.

Next, we used the same regression-based approach to test whether *incident*

cardiomyopathy was increased among individuals with (m)dCAD compared to CAD alone. All

individuals with cardiomyopathy coded prior to depression or CAD (N = 14,583) were excluded.

Hence the cardiomyopathy exposure was required to be coded after both depression and CAD.

This resulted in a total of 2,345 cardiomyopathy cases and 45,330 cardiomyopathy controls. We

then fitted two multivariable logistic regression models to test whether depression increased

the odds of incident cardiomyopathy among patients with (m)dCAD compared to patients with

CAD alone, after adjusting for the same previously described confounders.

<u>Sensitivity analyses using Severe Depression.</u>

Previous literature points towards progression and worsening of CAD with increasing

depression severity. To test whether cardiomyopathy more commonly co-occurred with severe

depression, we redefined our exposure using a stricter MDD definition requiring the presence

of 296.22 phecode and ICD9/10 codes (Table S8) which dropped the sample size from 57,069

depression-exposed patients to 41,423 MDD-exposed patients. The same regression models

described above were fitted to the data.

<u>Phenotypic Replication in MGB and *All of Us* Data</u>

We replicated the EHR analyses in two external cohorts, *All of Us* and MGB. We used the

same phecode based definitions to define our inclusion and exclusion criteria, case and control

labels, and exposures. Sensitivity analyses were similarly performed in these data by restricting

the exposure definition to include individuals with only severe depression.

Results

Genes Associated with Both Depression and CAD

We intersected the 22,207 predicted expression gene models with the summary

statistics of CAD and depression phenotypes as described above. While the tissues that best

predicted gene expression differed between CAD and depression (Figure S4); the mean

(Spearman's rank = 0.433), standard deviation (Spearman's rank = 0.565), minimum

(Spearman's rank = 0.389), and maximum (Spearman's rank = 0.373) association Z-score

statistics demonstrated strong correlation between depression and CAD across all tissues

tested (Figure S3).

Results from the 20,971 gene-based tests of association with CAD, and 20,945 gene-

based tests of association with depression are available in Table S2 and Table S3,

respectively[23,24]. We identified a total of 1,455 genes significantly associated with CAD (p <

2.38e-06) and 928 genes significantly associated with depression (p < 2.38e-06) illustrated in

Figures S1 and S2, respectively. We next identified the genes that were significantly associated

with *both* depression and CAD. A total of 20,944 genes were tested in common between

depression and CAD, and of these, 185 genes identified by their gene names were significantly

associated with *both* CAD and depression (Figure 2; Table S4). The genes associated with both

depression and CAD were distributed across the genome (Figure 2).

Enrichment and Pathway Analysis of 185 Genes Associated with Both Depression and CAD

We found that there were three times more genes associated with both CAD and

depression than expected by chance given the number of genes significantly associated with

each phenotype independently (hypergeometric test, p<1.718e-43) (Figure 3). Inflammatory

(FDR q-value < 0.05) and cardiomyopathy-associated pathways (FDR q value < 0.05) were

overrepresented among genes associated with both CAD and depression (Table 1). Five genes

from the shared set of 185 (2.7%) were annotated to cardiomyopathy-associated pathways.

Four of the 5 genes (*ATP2A2, ITGB4, SGCD*, and *CACNB4)* were annotated to all three

cardiomyopathy pathways (Table S4). Thirteen additional genes (7%) were annotated to

adaptive immune pathways (Table S4).

Clinical Cardiomyopathy in (m)dCAD

Analyses performed in the EHR returned significant differences in the prevalence of

cardiomyopathy between depression-only, CAD-only and (m)dCAD cohorts (Chisq P < 2.2e-16)

(Table S5). Almost 15% of individuals with (m)dCAD had a cardiomyopathy diagnosis, compared

to 11.2% in the CAD cohort and only 1.59 % in the depression cohort. The results remained

significant when we compared only the (m)dCAD group to the CAD group (Fisher's exact test p <

2.2e-16) (Table S5). We then replicated these findings in the MGH EHR and the All of Us Data.

We next restricted the depression phenotype to major depression (phecode 296.22) and

observed the same pattern in the prevalence of cardiomyopathy between the groups (Table

S6).

Prevalence of Clinical Cardiomyopathy after Adjusting for known Confounders

Results of the multivariable logistic model indicate that there is a 27% increase in the

odds of prevalent cardiomyopathy with a diagnosis of (m)dCAD compared to CAD after

adjusting for age, race, sex, hypertension diagnosis, smoking status, type-2-diabetes and BMI

(see Methods for details) (p-value = 3.6e-09, OR = 1.27, 95% CI = 1.17-1.3). This finding was

replicated in the *All of Us* (p-value = 0.012, OR = 1.16, 95%CI = 1.03-1.30) and MGH (p-value <

2e-16, OR = 1.32, 95%CI = 1.28-1.37) data sets.

Sensitivity analyses restricting the criteria for depression to "major depression"

preserved the effect estimate and significance of the original finding (OR = 1.14, 95%CI = 1.06-

1.26, p = 6.5e-03)(Figure 4). This finding was again replicated in the MGH cohort (OR = 1.23,

95%CI = 1.13-1.18, p < 2e-16). While the effect estimate was similar in the *All of Us* data set, the

finding did not reach statistical significance likely due to a reduced sample size (OR = 1.13,

95%CI = 0.97-1.32, p-value = 0.12)

<u>Rate of Incident Cardiomyopathy in (m)dCAD compared to CAD</u>

Lastly, we tested the hypothesis that (m)dCAD is a risk factor for the development of

subsequent cardiomyopathy. Using a multivariable logistic regression model, we found no

increase in the odds of incident cardiomyopathy among (m)dCAD patients compared to CAD

patients, after adjusting for known confounders in the VUMC EHR (OR = 0.96, 95% CI = 0.84-

1.09, p-value = 0.53) (Figure 5) and in the *All of Us* data (OR = 0.864, 95%C.I. = 0.730-1.021, p-

value = 0.086). In the MGH data, not only did we observe a lack of evidence for increased

incident cardiomyopathy subsequent to (m)dCAD, in fact we observed that (m)dCAD cases were

significantly *less* likely to be diagnosed with new onset cardiomyopathy compared to CAD alone

(OR = 0.783, 95%C.I. = 0.743-0.825, p-value < 2e-16).

After restricting the definition of depression to "major depression" in the VUMC data,

the odds of incident cardiomyopathy were elevated but not significantly so (OR = 1.16, 95% C.I.

= 1.00-1.34, p-value = 0.04). However, again, in the *All of Us* (OR = 0.66, 95% C.I. = 0.51-0.84, p-

value = 9e-4) and MGH (OR = 0.54, 95% C.I. = 0.50-0.58, p-value < 2 e-16) data, the rate of

incident cardiomyopathy was lower in (m)dCAD than in CAD alone.

<u>Discussion</u>

Depression and CAD are highly comorbid conditions and the molecular mechanisms

underlying this common comorbidity remain understudied. Here we present an integrative

genotypic approach to identify genes that map to SNP associations for each condition, followed

by a phenotypic analysis to test a hypothesis motivated by the genetic findings. By performing a

cross-tissue transcriptome-wide association scan using large scale GWAS data for depression

and CAD, we identified 185 genes (three time more than expected by chance) that were

significantly associated with both depression and CAD. Interestingly, the genes associated with

both phenotypes were not necessarily those most strongly associated with depression or CAD

independently. On balance, these results suggest that comorbid (m)dCAD may have a partially

unique genetic architecture which overlaps a subset of genes associated with depression and

CAD.

Pathway analyses indicate that the genes involved in (m)dCAD are enriched for

inflammatory and cardiomyopathy-associated pathways. Specifically, we observed an

enrichment for adaptive immune system genes which can be understood in the context of

previous studies that have highlighted immune dysfunction in both depression and CAD[15,29–36].

Moreover, research has shown that depression is associated with low-grade chronic

inflammation whereas CAD has phases of both, acute and chronic inflammation[36–38]. Hence the

enrichment of adaptive immune system genes suggests that depression and CAD could be

linked through exposure to low-grade chronic inflammation.

There were six genes *ATP2A2, ITGB4, SGCD, CACNB4, ACTN2*, and *TGFB1* associated with

both CAD and depression, which are known to be involved in cardiomyopathy (Table S4).

Differential expression of *ATP2A*, which encodes a Ca^{2+} pump on the endoplasmic reticulum, is

associated with cardiac phenotypes including dilated cardiomyopathy[39,,40]; and heterozygous

conditional knockout mice demonstrate an essential role for *ATP2A* in neuronal calcium

homeostasis resulting in behavioral phenotypes[41]. Similarly, *CACNB4* is the one of the most

abundant voltage-gated calcium channel subunits expressed in the brain where it is critical for

presynaptic signaling, and co-located in the heart where early data suggests it may be involved

in cardiac contraction[42–44]. The gene locus was also recently implicated in idiopathic

cardiomyopathy in individuals of African-American ancestry[45]. *ACTN2*, a cardiac-specific

structural protein, is classically involved in familial hypertrophic, dilated, and arrhythmogenic

cardiomyopathy[46–48] while *TGFB1* is a cytokine with a variety of cellular functions implicated in

cardiac hypertrophy and hypertrophic cardiomyopathy along with congenital heart disease[49,50].

Mutations in delta-sarcoglycan (*SGCD)* result in severe neuromuscular disease in humans and

knockout mice develop early progressive cardiomyopathy and dilated cardiomyopathy[51,52].

However, less is known about the impact of differences in expression of these genes (*ACTN2*,

TGFB1, and *SGCD*) on depression.

Interpreted in the context of previous studies, our genetic findings suggest that

depression and CAD could share low grade chronic inflammation[36,53–55]. Moreover, genetic

results of our study raised the hypothesis that a predisposition to both depression and CAD

(clinically observed as (m)dCAD) may further predispose individuals to cardiomyopathy.

Canonically, viral infections are considered the most common trigger and cause of

inflammatory cardiomyopathy thus leading to immune mechanisms which potentially damage

the myocardial function[56–63]. However, an alternative model consistent with our findings could

position chronic low-grade inflammation as a shared risk factor for depression, CAD, and

cardiomyopathy. We investigated the hypothesis that cardiomyopathy co-occurs more

commonly with (m)dCAD than with CAD, by harnessing the power of large-scale electronic

health record data at VUMC, MGB, and *All of Us*. These three systems represent both hospital

ascertainment (VUMC and MGB) and volunteer ascertainment (*All of Us*). Results of these

analyses suggest that while prevalent cardiomyopathy does in fact co-occur more frequently

with (m)dCAD than with CAD alone, the order of events remains unclear. For example, it

remains possible that (a) cardiomyopathy increases the risk of co-morbid depression in CAD, (b)

treatment for depression provides some protection against subsequent cardiomyopathy, or (c)

both cardiomyopathy and (m)dCAD share additional risk factors. While our work demonstrating

the clinical co-occurrence suggests that cardiomyopathy patients may benefit from depression

screening, future work is needed to disentangle their precise relationship and inform clinically

translatable mitigation strategies.

Despite its strengths, our study is limited by the well-established caveats of EHR based

phenotyping which itself suffers from individual bias of the clinician. TWAS analyses rely on

SNP-based predictive models of mRNA trained using mostly European-ancestry individuals in

GTEx v8 and assumes additivity of SNP effects on gene expression, which ignores the possibility

of epistatic and gene-environment interactions. Online pathway tools are prone to knowledge

bias in selection of the "validated" genes annotated to pathways.

Nevertheless, these analyses highlight the unique genetic and phenotypic architecture

of (m)dCAD compared to CAD and depression alone. We add to the literature the observation

that prevalent, but perhaps not incident cardiomyopathy, is also more common in patients with

(m)dCAD compared to CAD alone. Importantly, this hypothesis was motivated by genetic

findings suggesting that the genes associated with both depression and CAD are enriched for

pathways with a known role in immune and cardiomyopathy-associated biological processes.

This data-driven approach highlights the power of *in silico* transcriptome-wide studies to

motivate hypotheses that can be tested in large EHR databases.

Acknowledgements

Funding

KS is funded by the American Heart Association Fellowship AHA827137. LKD is supported by

R56MH120736. JWS and LKD are supported in part by NIMH R01 H118233. JMS is funded by

1F31MH124306-01A1. QSW was supported by NIH 1R01HL140074.

CTSA (SD, Vanderbilt Resources)

The deidentified EHR used at VUMC was supported by the National Center for Research

Resources, Grant UL1 RR024975-01, and is now at the National Center for Advancing

Translational Sciences, Grant 2 UL1 TR000445-06. The content is solely the responsibility of the

authors and does not necessarily represent the official views of the NIH.

BioVU

The dataset(s) used for the analyses described were obtained from Vanderbilt University

Medical Center's BioVU which is supported by numerous sources: institutional funding, private

agencies, and federal grants. These include the NIH funded Shared Instrumentation Grant

S10RR025141; and CTSA grants UL1TR002243, UL1TR000445, and UL1RR024975. Genomic data

are also supported by investigator-led projects that include U01HG004798, R01NS032830,

RC2GM092618, P50GM115305, U01HG006378, U19HL065962, R01HD074711; and additional

funding sources listed at https://victr.vumc.org/biovu-funding/.

The *All of Us* Research Program is supported by grants through the National Institutes of

Health, Office of the Director: Regional Medical Centers: 1 OT2 OD026549; 1 OT2 OD026554;

1 OT2 OD026557; 1 OT2 OD026556; 1 OT2 OD026550; 1 OT2 OD026552; 1 OT2 OD026553;

1 OT2 OD026548; 1 OT2 OD026551; 1 OT2 OD026555; IAA#: AOD 16037; Federally Qualified

Health Centers: HHSN 263201600085U; Data and Research Center: 5 U2C OD023196;

Biobank: 1 U24 OD023121; The Participant Center: U24 OD023176; Participant Technology

Systems Center: 1 U24 OD023163; Communications and Engagement: 3 OT2 OD023205; 3

OT2 OD023206; and Community Partners: 1 OT2 OD025277; 3 OT2 OD025315; 1 OT2

OD025337; 1 OT2 OD025276. In addition to the funded partners, the *All of Us Research

Program* would not be possible without the contributions made by its participants.

Declarations

<u>Contributions</u>

K.S. and L.K.D. conceptualized and designed the work. K.S, J.M.S, and H.L. implemented the

computational procedures and performed data analysis. N.J.C, Q.S.W., and E.C.H provided

important clinical and intellectual insights. All authors read, edited, and approved the final

manuscript.

<u>Corresponding author</u>

Correspondence to Lea K. Davis at lea.k.davis@vumc.org

Ethics declarations

<u>Ethics approval and consent to participate</u>

This study was reviewed by the VUMC IRB and designated as non-human subjects research

because of the use of fully de-identified data (IRB# 190418 and IRB# 201609).

<u>Competing interests</u>

JWS is a member of the Scientific Advisory Board of Sensorium Therapeutics (with equity), and

has received an honorarium for an internal seminar Tempus Labs. He is PI of a collaborative

study of the genetics of depression and bipolar disorder sponsored by 23andMe for which

23andMe provides analysis time as in-kind support but no payments.

Supplementary Materials

Supplementary Methods

Supplementary Figure 1

Supplementary Figure 2

Supplementary Figure 3

Supplementary Figure 4

Supplementary Table 1

Supplementary Table 2

Supplementary Table 3

Supplementary Table 4

Supplementary Table 5

Supplementary Table 6

References

1. Kendler, K. S., Gardner, C. O., Fiske, A. & Gatz, M. Major depression and coronary artery

disease in the Swedish twin registry: phenotypic, genetic, and environmental sources of

comorbidity. *Arch. Gen. Psychiatry* **66**, 857–863 (2009).

2. Glassman, A. H. Depression and cardiovascular comorbidity. *Dialogues Clin. Neurosci.* **9**, 9–17

(2007).

3. Sullivan, M. *et al.* Depression in coronary heart disease. What is the appropriate diagnostic

threshold? *Psychosomatics* **40**, 286–292 (1999).

4. O'Neil, A. *et al.* Depression is a risk factor for incident coronary heart disease in women: An

18-year longitudinal study. *J. Affect. Disord.* **196**, 117–124 (2016).

5. Weeke, A., Juel, K. & Vaeth, M. Cardiovascular death and manic-depressive psychosis. *J.*

Affect. Disord. **13**, 287–292 (1987).

6. Dennis, J. *et al.* Genetic risk for major depressive disorder and loneliness in sex-specific

associations with coronary artery disease. *Mol. Psychiatry* **26**, 4254–4264 (2021).

7. Mazereeuw, G. *et al.* Platelet activating factors in depression and coronary artery disease: a

potential biomarker related to inflammatory mechanisms and neurodegeneration. *Neurosci.*

Biobehav. Rev. **37**, 1611–1621 (2013).

8. McCaffery, J. M. *et al.* Common genetic vulnerability to depressive symptoms and coronary

artery disease: a review and development of candidate genes related to inflammation and

serotonin. *Psychosom. Med.* **68**, 187–200 (2006).

9. Upadhyay, R. K. Emerging risk biomarkers in cardiovascular diseases and disorders. *J. Lipids*

2015, 971453 (2015).

10.   Shimokawa, H., Aarhus, L. L. & Vanhoutte, P. M. Porcine coronary arteries with

regenerated endothelium have a reduced endothelium-dependent responsiveness to

aggregating platelets and serotonin. *Circ. Res.* **61**, 256–270 (1987).

11.   Brydon, L., Magid, K. & Steptoe, A. Platelets, coronary heart disease, and stress. *Brain.*

Behav. Immun. **20**, 113–119 (2006).

12.   Huang, M. *et al.* Longitudinal association of inflammation with depressive symptoms: A

7-year cross-lagged twin difference study. *Brain. Behav. Immun.* **75**, 200–207 (2019).

13.   Beydoun, M. A. *et al.* White blood cell inflammatory markers are associated with

depressive symptoms in a longitudinal study of urban adults. *Transl. Psychiatry* **6**, e895

(2016).

14.   Kim, J.-M. *et al.* Changes in pro-inflammatory cytokine levels and late-life depression: A

two year population based longitudinal study. *Psychoneuroendocrinology* **90**, 85–91 (2018).

15.   Bränn, E. *et al.* Inflammatory markers in late pregnancy in association with postpartum

depression-A nested case-control study. *Psychoneuroendocrinology* **79**, 146–159 (2017).

16.   Bremmer, M. A. *et al.* Inflammatory markers in late-life depression: results from a

population-based study. *J. Affect. Disord.* **106**, 249–255 (2008).

17.   Martínez-Cengotitabengoa, M. *et al.* Peripheral Inflammatory Parameters in Late-Life

Depression: A Systematic Review. *Int. J. Mol. Sci.* **17**, E2022 (2016).

18.   Gheysarzadeh, A. *et al.* Serum-based microRNA biomarkers for major depression: MiR-

16, miR-135a, and miR-1202. *J. Res. Med. Sci. Off. J. Isfahan Univ. Med. Sci.* **23**, 69 (2018).

19.   Schmidt, H. D., Shelton, R. C. & Duman, R. S. Functional biomarkers of depression:

diagnosis, treatment, and pathophysiology. *Neuropsychopharmacol. Off. Publ. Am. Coll.*

Neuropsychopharmacol. **36**, 2375–2394 (2011).

20.   Nurden, A. T. The biology of the platelet with special reference to inflammation, wound

healing and immunity. *Front. Biosci. Landmark Ed.* **23**, 726–751 (2018).

21.   Tsao, C.-W., Lin, Y.-S., Chen, C.-C., Bai, C.-H. & Wu, S.-R. Cytokines and serotonin

transporter in patients with major depression. *Prog. Neuropsychopharmacol. Biol. Psychiatry*

30, 899–905 (2006).

22.   Pandey, G. N. *et al.* Hyperactive phosphoinositide signaling pathway in platelets of

depressed patients: effect of desipramine treatment. *Psychiatry Res.* **105**, 23–32 (2001).

23.   van der Harst, P. & Verweij, N. Identification of 64 Novel Genetic Loci Provides an

Expanded View on the Genetic Architecture of Coronary Artery Disease. *Circ. Res.* **122**, 433–

443 (2018).

24.   Howard, D. M. *et al.* Genome-wide meta-analysis of depression identifies 102

independent variants and highlights the importance of the prefrontal brain regions. *Nat.*

Neurosci. **22**, 343–352 (2019).

25.   Barbeira, A. N. *et al.* Integrating predicted transcriptome from multiple tissues improves

association detection. *PLOS Genet.* **15**, e1007889 (2019).

26.   Lonsdale, J. *et al.* The Genotype-Tissue Expression (GTEx) project. *Nat. Genet.* **45**, 580–

585 (2013).

27.   Bowton, E. *et al.* Biobanks and Electronic Medical Records: Enabling Cost-Effective

Research. *Sci. Transl. Med.* **6**, (2014).

28.   The All of Us Research Program Investigators. The "All of Us" Research Program. *N. Engl.*

J. Med. **381**, 668–676 (2019).

29.   McCaffery, J. M. *et al.* Common genetic vulnerability to depressive symptoms and

coronary artery disease: a review and development of candidate genes related to

inflammation and serotonin. *Psychosom. Med.* **68**, 187–200 (2006).

30.   Upadhyay, R. K. Emerging risk biomarkers in cardiovascular diseases and disorders. *J.*

Lipids **2015**, 971453 (2015).

31.   Shimokawa, H., Aarhus, L. L. & Vanhoutte, P. M. Porcine coronary arteries with

regenerated endothelium have a reduced endothelium-dependent responsiveness to

aggregating platelets and serotonin. *Circ. Res.* **61**, 256–270 (1987).

32.   Brydon, L., Magid, K. & Steptoe, A. Platelets, coronary heart disease, and stress. *Brain.*

Behav. Immun. **20**, 113–119 (2006).

33.   Huang, M. *et al.* Longitudinal association of inflammation with depressive symptoms: A

7-year cross-lagged twin difference study. *Brain. Behav. Immun.* **75**, 200–207 (2019).

34.   Beydoun, M. A. *et al.* White blood cell inflammatory markers are associated with

depressive symptoms in a longitudinal study of urban adults. *Transl. Psychiatry* **6**, e895

(2016).

35.   Kim, J.-M. *et al.* Changes in pro-inflammatory cytokine levels and late-life depression: A

two year population based longitudinal study. *Psychoneuroendocrinology* **90**, 85–91 (2018).

36.   Sealock, J. M. *et al.* Use of the PsycheMERGE Network to Investigate the Association

Between Depression Polygenic Scores and White Blood Cell Count. *JAMA Psychiatry* **78**, 1365

(2021).

37.   Twig, G. *et al.* White Blood Cell Count and the Risk for Coronary Artery Disease in Young

Adults. *PLoS ONE* **7**, e47183 (2012).

38.   Zebrack, J. S., Muhlestein, J. B., Horne, B. D. & Anderson, J. L. C-reactive protein and

angiographic coronary artery disease: independent and additive predictors of risk in subjects

with angina. *J. Am. Coll. Cardiol.* **39**, 632–637 (2002).

39.   Lu, Q. *et al.* Intranuclear cardiac troponin I plays a functional role in regulating Atp2a2

expression in cardiomyocytes. *Genes Dis.* S2352304221000611 (2021)

doi:10.1016/j.gendis.2021.04.007.

40.   Alimadadi, A., Munroe, P. B., Joe, B. & Cheng, X. Meta-Analysis of Dilated

Cardiomyopathy Using Cardiac RNA-Seq Transcriptomic Datasets. *Genes* **11**, 60 (2020).

41.   Nakajima, K. *et al.* Brain-specific heterozygous loss-of-function of ATP2A2, endoplasmic

reticulum Ca2+ pump responsible for Darier's disease, causes behavioral abnormalities and a

hyper-dopaminergic state. *Hum. Mol. Genet.* **30**, 1762–1772 (2021).

42.   Coste de Bagneaux, P. *et al.* A homozygous missense variant in CACNB4 encoding the

auxiliary calcium channel beta4 subunit causes a severe neurodevelopmental disorder and

impairs channel and non-channel functions. *PLOS Genet.* **16**, e1008625 (2020).

43.   Andrade, A. *et al.* Genetic Associations between Voltage-Gated Calcium Channels and

Psychiatric Disorders. *Int. J. Mol. Sci.* **20**, 3537 (2019).

44.   Kanehisa, M. *et al.* KEGG for linking genomes to life and the environment. *Nucleic Acids

Res.* **36**, D480–D484 (2007).

45.   Xu, H. *et al.* A Genome-Wide Association Study of Idiopathic Dilated Cardiomyopathy in

African Americans. *J. Pers. Med.* **8**, 11 (2018).

46.   Good, J.-M. *et al.* ACTN2 variant associated with a cardiac phenotype suggestive of left-

dominant arrhythmogenic cardiomyopathy. *Hear. Case Rep.* **6**, 15–19 (2020).

47.   Haywood, N. J. *et al.* Hypertrophic cardiomyopathy mutations in the calponin-homology

domain of ACTN2 affect actin binding and cardiomyocyte Z-disc incorporation. *Biochem. J.*

473, 2485–2493 (2016).

48.   Tiso, N. Identification of mutations in the cardiac ryanodine receptor gene in families

affected with arrhythmogenic right ventricular cardiomyopathy type 2 (ARVD2). *Hum. Mol.*

Genet. **10**, 189–194 (2001).

49.   Patel, R. *et al.* Variants of Trophic Factors and Expression of Cardiac Hypertrophy in

Patients with Hypertrophic Cardiomyopathy. *J. Mol. Cell. Cardiol.* **32**, 2369–2377 (2000).

50.   Yadav, M. L., Bhasker, A. N., Kumar, A. & Mohapatra, B. Identification and

characterization of genetic variants of TGFB1 in patients with congenital heart disease. *Meta*

Gene **31**, 100987 (2022).

51.   Bauer, R., MacGowan, G. A., Blain, A., Bushby, K. & Straub, V. Steroid treatment causes

deterioration of myocardial function in the -sarcoglycan-deficient mouse model for dilated

cardiomyopathy. *Cardiovasc. Res.* **79**, 652–661 (2008).

52.   Rutschow, D. *et al.* S151A δ-sarcoglycan mutation causes a mild phenotype of

cardiomyopathy in mice. *Eur. J. Hum. Genet.* **22**, 119–125 (2014).

53.   Lynall, M.-E. *et al.* Peripheral Blood Cell–Stratified Subgroups of Inflamed Depression.

Biol. Psychiatry **88**, 185–196 (2020).

54.   McNally, L., Bhagwagar, Z. & Hannestad, J. Inflammation, Glutamate, and Glia in

Depression: *A Literature Review*. *CNS Spectr.* **13**, 501–510 (2008).

55.   Troubat, R. *et al.* Neuroinflammation and depression: A review. *Eur. J. Neurosci.* **53**,

151–171 (2021).

56.   Eitel, I. *et al.* Inflammation in takotsubo cardiomyopathy: insights from cardiovascular

magnetic resonance imaging. *Eur. Radiol.* **20**, 422–431 (2010).

57.   Adamo, L., Rocha-Resende, C., Prabhu, S. D. & Mann, D. L. Reappraising the role of

inflammation in heart failure. *Nat. Rev. Cardiol.* **17**, 269–285 (2020).

58.   Maisch, B., Ristic, A. D. & Pankuweit, S. [Inflammatory cardiomyopathy and

myocarditis]. *Herz* **42**, 425–438 (2017).

59.   Krejci, J., Mlejnek, D., Sochorova, D. & Nemec, P. Inflammatory Cardiomyopathy: A

Current View on the Pathophysiology, Diagnosis, and Treatment. *BioMed Res. Int.* **2016**,

4087632 (2016).

60.   Tschöpe, C. *et al.* Myocarditis and inflammatory cardiomyopathy: current evidence and

future directions. *Nat. Rev. Cardiol.* **18**, 169–193 (2021).

61.   Eitel, I. *et al.* Clinical characteristics and cardiovascular magnetic resonance findings in

stress (takotsubo) cardiomyopathy. *JAMA* **306**, 277–286 (2011).

62.   Scally, C. *et al.* Myocardial and Systemic Inflammation in Acute Stress-Induced

(Takotsubo) Cardiomyopathy. *Circulation* **139**, 1581–1592 (2019).

63.   Rroku, A., Grahl, S., Landmesser, U. & Heidecker, B. A case report of myocardial

inflammation in takotsubo syndrome. A chicken-or-the-egg phenomenon. *Int. J. Cardiol.*

Heart Vasc. **39**, 100958 (2022).

Figures and Tables

Figure 1

Title: Overall Schematic of the Study

Legend : We performed a transcriptome-wide association study (TWAS) of genetically regulated expression (GReX) using the GTEx v.8 database and genome-wide summary statistics of Depression and Coronary Artery Disease separately. We derived genes that were shared between Depression and CAD, we performed pathway and enrichment analyses. Our results show that genes associated with both depression and CAD are associated with cardiomyopathy associated phenotypes.

Figure 2

Title: Genes associated with Depression and CAD using S-MultiXcan

Legend: A Miami plot of genes associated with both Depression and CAD via S-MultiXcan Each data point represents a gene grouped by chromosome (x-axis) and p value (y-axis) of the association with the phenotype. The top half of the graph are genes associated with CAD and the lower half of the graph represents genes associated with Depression. The purple dots represent the 185 genes shared between Depression and CAD. Genes with −log(p values) greater that 50 are labelled. The light and dark grey represents the non-shared genes on alternating chromosomes with light grey with being the non-shared genes on odd chromosomes and dark grey representing the non-shared genes on the even numbered chromosomes

Genes Associated with CAD : 1,455

Genes Associated exclusively with CAD : 1,270

Genes Associated with Depression : 928

Genes Associated exclusively with Depression : 743

Genes Shared Between CAD and Depression : 185

3x Enrichment of Shared Association (hypergeometric test p < 1.718e-43)

Figure 3

Title : Enrichment test of the genes shared between Depression and CAD

Legend: Eulerr Plot to highlight the results of enrichment test of the genes associated with both depression and CAD. The grey circle represents the set of 20,944 genes that were tested for association with both phenotypes. The red portion represents the 1,270 genes significantly associated with CAD only. The blue portion represents the 743 genes significantly associated with depression only. The purple portion represents the 185 genes associated with both depression and CAD. Red + purple represents all CAD associated genes (1455) and blue + purple represents all genes associated with depression (928).

Figure 4

Title: Forest plot illustrating odds of prevalent cardiomyopathy in (m)dCAD compared to CAD

Legend: The association between (m)dCAD vs CAD and prevalent cardiomyopathy after controlling for race, median age across the medical record, sex, T2D, hypertension, and smoking (ever/never) at each of the three sites (VUMC, MGB, and All of Us). Purple represents results from an analysis in which depression was broadly defined while light pink represents results from an analysis restricted to major depression. Whiskers indicate 95% CIs.

Figure 5

Title: Forest plot illustrating odds of incident cardiomyopathy in (m)dCAD compared to CAD

Legend: The association between (m)dCAD vs CAD and incident cardiomyopathy after controlling for race, median age across the medical record, sex, T2D, hypertension, and smoking (ever/never) at each of the three sites (VUMC, MGB, and All of Us). Purple represents results from an analysis in which depression was broadly defined while light pink

Gene Set Name	No. of Genes in the set (K)	Number of Genes in Overlap (k)	k/K	FDR Value
Post-translational protein modification	1435	22	0.0152	1.39e-03
Arrhythmogenic right ventricular cardiomyopathy (ARCV)	76	5	0.0657	1.87e-02
Transport of small molecules	728	13	0.0179	1.87e-02
Hypertrophic cardiomyopathy (HCM)	83	5	0.0602	2.13e-02
Dilated cardiomyopathy	90	5	0.0556	2.62e-02
Adaptive Immune System	825	13	0.0158	3.79e-02

644
645

646
647 Table 1: Gene Set Enrichment Analysis of the Shared Genes

648
649 Legend: We used the 185 genes shared between Depression and CAD as the input for GESA (Canonical Pathways)
650 browser and identified that the shared genes are associated with immune and cardiomyopathy associated
651 phenotypes. K refers to the number of genes in the GSEA database for that particular pathway. k refers to the
652 number of genes from our shared 185 gene-set in the particular pathway

653
654

	Depression (broad)	Major Depression	CAD	Depression and CAD	Major Depression and CAD
Sample sizes					
Total (N)	57,069	41,423	47,349	6,725	4,175
Cardiomyopathy	809 (1.41%)	537 (1.29%)	5,314 (11.22%)	1,001 (14.88%)	589 (14.10%)
Demographics					
Female (%)	68.64	69.1	32.86%	48.91%	47.04%
Median Age, years (IQR)	41(24.5 − 65.5)	39 (22.5 − 55.5)	68 (60 − 76)	65 (56.5-72.5)	64 (56 − 72)
Median BMI (IQR)	27.34	27.28	28.81	29.29	29.68
Underweight	2,071 (3.63%)	1,655 (4.0%)	377 (0.79%)	64 (0.95%)	39 (0.93%)
Normal	17,437 (30.56%)	12,964 (31.3%)	8,673 (18.31%)	1,320 (19.62%)	794 (19.02%)
Overweight	14,154 (24.80%)	10,204 (24.63%)	15,520 (32.77%)	1,979 (29.43%)	1,291 (30.93%)
Obese	19,247 (33.73%)	14,203 (34.28%)	17,423 (36.8%)	2,812 (41.81%)	1,951 (46.73%)
Unknown	4,160 (7.29%)	2,397 (5.78%)	5,356 (11.31%)	550 (8.18%)	100 (2.4%)
Cardiovascular Comorbidities					
Hypertension (N, %)	19,784 (34.66%)	13,513 (32.62%)	38,905 (82.17%)	6,200 (92.2%)	3,837 (91.9%)
Type 2 Diabetes (N, %)	7,452 (13.06%)	5,116 (12.35%)	15,207 (32.11%)	3,227 (47.99%)	2,062 (49.39%)
Tobacco Use Disorder (N, %)	8,363 (14.65%)	6,555 (15.82%)	8,482 (17.91%)	2,399 (35.67%)	1,816 (43.5%)

Table 2: Demographic table for Phenotypes in VUMC

This table describes the demographics for Depression, Major Depression, CAD, Comorbid Depression-CAD and Comorbid Major Depression-CAD in VUMC EHR data.

Supplementary Materials

of

Genes associated with depression and coronary artery disease are enriched for

inflammation and cardiomyopathy-associated pathways.

Kritika Singh[1,2], Hyunjoon Lee[3,4,5]*, Julia M Sealock[1,2]*, Tyne Miller-Flemming[1,2], Peter

Straub[1,2], Nancy J. Cox[1,2], Quinn S. Wells[6], Jordan W. Smoller[3,4,5], Emily C. Hodges[2,7], Lea

K. Davis[1,2,8,9,10]

*These authors contributed equally

#Corresponding author

[1]Division of Genetic Medicine, Department of Medicine
Vanderbilt University Medical Center
Nashville, TN, 37232, USA
668
669 [2]Vanderbilt Genetics Institute
670 Vanderbilt University Medical Center
671 Nashville, TN, 37232, USA
672
673 [3]Psychiatric and Neurodevelopmental Genetics Unit
674 Center for Genomic Medicine
675 Massachusetts General Hospital
676 Boston, MA, 02114, USA
677
678 [4]Center for Precision Psychiatry
679 Department of Psychiatry
680 Massachusetts General Hospital
681 Boston, MA, 02114, USA
682
683 [5]Stanley Center for Psychiatric Research
684 Broad Institute of Harvard and MIT
685 Cambridge, MA, 02114,USA
686
[6]Division of Cardiovascular Medicine, Department of Medicine,
Vanderbilt University Medical Center,

Nashville, TN, 37232, USA

[7]Department of Biochemistry,

Vanderbilt University School of Medicine,

Nashville, TN, 37232, USA

[8]Department of Molecular Physiology and Biophysics

Vanderbilt University Medical Center

Nashville, TN, 37232, USA

[9]Department of Psychiatry and Behavioral Sciences

Vanderbilt University Medical Center

Nashville, TN, 37232, USA

[10]Departments of Medicine and Biomedical Informatics

Vanderbilt University Medical Center

Nashville, TN, 37232, USA

Description of Clinical Populations

Vanderbilt University Medical Center (VUMC) Electronic Health Record (EHR)

Vanderbilt University Medical Center (VUMC) is a tertiary care center that provides

inpatient and outpatient care in middle Tennessee and surrounding communities. The VUMC

electronic health record (EHR) system was established in 1990 and includes data on billing

codes from the International Classification of Diseases, 9th and 10th editions (ICD-9 and ICD-

10), Current Procedural Terminology (CPT) codes, laboratory values, reports, and clinical

documentation. A fully de-identified mirror image of the EHR, called the Synthetic Derivative, is

available to Vanderbilt faculty for research purposes. A data floor (i.e., "medical home")

heuristic of any five codes on different days over a period of at least three years was imposed

to enrich the sample for primary care.

Massachusetts General Hospital (MGH)

Mass General Brigham (MGB) is a hospital network that includes Massachusetts General

Hospital, Brigham and Women's hospital, and other community and specialty hospitals in

Boston area. The data source of MGB EHR is MGB Research Patient Data Registry (RPDR;

https://rpdrssl.partners.org), an EHR database which spans more than 20 years of data from

over 6.5 million patients and includes data on diagnoses (billing codes; ICD-9 and ICD-10 codes),

procedures (CPT codes), laboratory values, and clinical notes. Data floors were applied to the

MGB RPDR to include only patients with at least one clinical note and three visits since 2005

with visit more than 30 days apart.

All of Us Research Program

All of Us Research Program, a population-based cohort that contains demographic, EHR,

and survey information on participants. Participants enroll digitally through the All of Us

website. After completion of the consent modules and enrollment, participants are given

several health-measuring surveys to be completed. As of July 2019, the All of Us program had

enrolled more than 175,000 core participants and more than 230,000 total participants.

Figure S1

Title: Genes associated with CAD using S-MultiXcan

Legend: A Miami plot of genes and SNPs associated with CAD via S-MultiXcan. Above the x-axis, each data point represents a gene grouped by chromosome (x-axis) and p value (y-axis) of the association with the phenotype. The light red and darl red are alternating colors for genes on odd and even chromosomes. Below the x-axis, each data point represents the SNPs associated with CAD from the input GWAS. Genes with –log(p values) greater that 50 are labelled. The black and grey are alternating colors for SNPs on odd and even chromosomes

736
737
738

739
740

Figure S2

Title: Genes associated with Depression using S-MultiXcan

Legend: A Miami plot of genes and SNPs associated with Depression via S-MultiXcan. Above the x-axis, each data point represents a gene grouped by chromosome (x-axis) and p value (y-axis) of the association with the phenotype. The light red and dark blue are alternating colors for genes on odd and even chromosomes Below the x-axis, each data point represents the SNPs associated with Depression from the input GWAS. Genes with –log(p values) greater that 50 are labelled. The black and grey are alternating colors for SNPs on odd and even chromosomes

Figure S3

Title: Correlation plots between the test statistics of Depression and CAD for the 185 genes associated with both the pheno-types

Legend: (a) Correlation Plot of Z Mean of Depression and CAD for the 185 genes shared between both the phenotypes (Spearman's coefficient = 0.433)
(b) Correlation Plot of Z Standard Deviation of Depression and CAD for the 185 genes shared between both the phenotypes (Spearman's coefficient = 0.565)
(c) Correlation Plot of Z Min of Depression and CAD for the 185 genes shared between both the phenotypes (Spearman's coefficient = 0.389)
(d) Correlation Plot of Z Max of Depression and CAD for the 185 genes shared between both the phenotypes (Spearman's coefficient = 0.373)

Figure S4

Title: Best Predicted Tissue Distribution of Genes Associated between Depression and CAD

Legend: (a) Tissue distribution of Best Predicted Tissue for genes associated with both Depression and CAD using SMultiXcan Results of CAD
(b) Tissue distribution of Best Predicted Tissue for genes associated with both Depression and CAD using SMultiXcan Results of Depression

744
745